company? Let’s change
that.
Don't see your company?
Create a company profileEikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring the effects of chemical compounds on the behavior of protein molecules in a live cellular environment, Eikon’s landmark assays facilitate the highly sensitive identification of compound-protein interactions that could not be identified through traditional assays, thereby unlocking otherwise intractable classes of proteins as drug targets. Furthermore, the ability to directly visualize protein mechanisms in disease coupled with the extraordinarily high-powered high-content data sets generated by Eikon’s drug-screening technology enable an unprecedented opportunity to quantitatively explore novel biology in the living cell. These insights facilitate creation and application of data-driven hypotheses to the discovery of life-saving therapies. Eikon is seeking adventurous, passionate and creative team members eager to apply their talents to empower interdisciplinary scientific exploration, inaugurate a radical drug-discovery paradigm, and ultimately create novel medicines. To learn more about open positions, please visit: https://eikontx.com/team#positions
Cylene Pharmaceuticals discovers, develops and commercializes small molecule drugs that target nucleolus and kill cancer cells.
Lipocine is a specialty pharmaceutical company that develops and commercializes pharmaceutical products.
CinRx Pharma is a mosaic of biotechnology companies supported by a dedicated funding mechanism designed to improve drug development success by accelerating promising new medicines to patients. Integrating our pre-clinical, clinical and operational expertise with multiple shots on goal, we customize the optimal development trajectory for each pipeline candidate – a drug development superhighway. Our deliberate approach to asset selection is driven by deep operational and scientific expertise combined with decades of experience treating patients and developing new drugs. We invest in candidate drugs that have the potential for transformational change in the way a disease area is treated and significantly improves the patient experience and quality of life.
AmbioPharm, a global peptide CDMO, was founded in 2005 and is headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at very small to very large scales. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) and generic peptide APIs under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA with excellent outcomes. Ambio is a drug development company with a rich and growing pipeline of proprietary drug development programs for bioequivalent and biosimilar versions of the world’s best-selling peptide drugs. Ambio Pharmaceuticals is the parent company of AmbioPharm, Inc. and Ambio, Inc.
About Enzyvant Enzyvant is a biopharmaceutical company making life-altering impact for people affected by rare disease, where communities are small, and the human need is immense. Enzyvant partners with these communities to accelerate development of transformative medicines, collaborating with academia, industry, physician associations, advocacy groups and government, because strong relationships make bold science possible. Enzyvant has capabilities spanning non-clinical and clinical development and commercialization and is developing in-house manufacturing. The company delivered one of the first Regenerative Medicine Advanced Therapy products and makes promising advances against some of the greatest challenges in immunology and cardiopulmonology. For more information about Enzyvant, visit www.Enzyvant.com.
We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
RxSolutions is a company that specializes in customized pharmaceutical reimbursement programs.
LENUS BIOSCIENCE SPAC targets to acquire a conglomerate of companies in the area of medical cannabis CBD)
AxoSim is an operator of a biomimetic neuroscience discovery platform used to develop a 3D cell-based platform.
Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with mast-cell mediated inflammatory diseases. By inhibiting KIT, we believe we can provide broad symptomatic relief to patients with a range of disorders, including chronic spontaneous urticaria and severe asthma
Turning Point Therapeutics is a structure-based drug design pharmaceutical company.
Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.
Evio is a pharmacy solutions startup that works with health plans to transform the medication experience for everyone: patients, providers, and the system at large. Using real world evidence, Evio will ensure every patient gets the right medication in a simple and affordable way
Nobelpharma develops medicines and medical devices with a focus on underserved patient populations and undertreated medical conditions. Visit our website at https://www.nobelpharma-us.com
Selkirk is a new aseptic Fill and Finish CMO located in the healthcare hub of the Pacific Northwest, and we are focused on providing the most reliable aseptic fill and finish services available. Our facility is purpose-built for contract manufacturing with unidirectional process flows, electronic batch records and the most advanced SKAN isolators and Bausch and Stroebel filling equipment. At Selkirk we believe that the safety and availability of drug products are the most important priorities for our clients. Selkirk was founded, designed, and built by a team of industry professionals with a passion for creating a newly imagined, first-in-class CMO facility. This group has grown into a multidisciplinary team of Quality and Manufacturing experts with an average of 20 years industry experience.
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from scientific discovery, to assessing safety, efficacy, and health care outcomes, to managing clinical trial logistics, to the development and manufacturing of the drug product.
Eye-Pharma, LLC is an ophthalmic drug company that is pioneering new brand and generic drug products.